Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

CRISPR-Cas9 gene editing technology has emerged as one of the most transformative advancements in medicine and biotechnology.

While we drown breakthrough-science in red tape, China has a laser-like focus on speeding up scientific progress and adopting ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

The Cell Shuttle was designed to help academic cell therapy developers by providing an integrated, automated solution.

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

Explore the advancements in stem cell therapy for neurodegenerative diseases. Discover market size, trends, and growth projections for 2035 with a focus on treatment innovations.

Previous skepticism turns to optimism as the first clinical trials for transplantation with genetically edited pig kidneys ...

Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in ... enables agility in life science discovery and ...

the first CRISPR-based therapy, in December 2023, the financial pressures continued amidst executive shifts, such as the departure of COO Julianne Bruno in March 2025. Finally, clinical trial ...